Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.054
Neutral
RSI(14)
49.741
Neutral
STOCH(KDJ)(9,3,3)
43.088
Sell
ATR(14)
0.157
Low Volatility
CCI(14)
-47.286
Neutral
Williams %R
65.909
Sell
TRIX(12,20)
0.408
Sell
StochRSI(14)
26.089
Sell
Evotec SE
EVO3.530USD
+0.010+0.28%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.25BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Evotec SE
Currency: USD Updated: 2026-02-06Key Insights
Evotec SE's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 141 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 5.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Evotec SE's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Evotec SE Highlights
StrengthsRisks
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Overvalued
The company’s latest PE is -7.16, at a high 3-year percentile range.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.56.
Analyst Rating
Based on
3
analysts
Hold
Current Rating
5.000
Target Price
+42.05%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Evotec SE is 7.41, ranking 111 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 191.55M, representing a year-over-year decrease of 5.70%, while its net profit experienced a year-over-year decrease of 15.65%.
Score
Financials
5.40
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.34
Operational Efficiency
10.00
Growth Potential
6.10
Shareholder Returns
7.19
Evotec SE's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Evotec SE is 6.98, ranking 193 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -7.16, which is -33.93% below the recent high of -4.73 and -526.83% above the recent low of -44.85.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 141/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Evotec SE is 6.67, ranking 330 out of 392 in the Biotechnology & Medical Research industry. The average price target is 5.00, with a high of 7.00 and a low of 3.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Hold
Current Rating
5.000
Target Price
+34.41%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
Evotec SE
EVO
3
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
24
Intellia Therapeutics Inc
NTLA
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Evotec SE is 6.02, ranking 285 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.81 and the support level at 3.32, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.596
Sell
MA10
3.650
Sell
MA20
3.640
Sell
MA50
3.342
Buy
MA100
3.495
Buy
MA200
3.731
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Evotec SE is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 2.97%, representing a quarter-over-quarter decrease of 0.00%. The largest institutional shareholder is CI Select Canadian Equity Fund, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Evotec SE is 3.24, ranking 160 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.82. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.82
VaR
+5.49%
240-Day Maximum Drawdown
+38.69%
240-Day Volatility
+56.75%
Return
Best Daily Return
60 days
+10.82%
120 days
+10.82%
5 years
+17.92%
Worst Daily Return
60 days
-6.81%
120 days
-15.74%
5 years
-31.63%
Sharpe Ratio
60 days
+0.74
120 days
-0.07
5 years
-0.16
Risk Assessment
Maximum Drawdown
240 days
+38.69%
3 years
+78.29%
5 years
--
Return-to-Drawdown Ratio
240 days
-0.54
3 years
-0.27
5 years
--
Skewness
240 days
+0.23
3 years
-0.67
5 years
-0.43
Volatility
Realised Volatility
240 days
+56.75%
5 years
--
Standardised True Range
240 days
+4.12%
5 years
--
Downside Risk-Adjusted Return
120 days
-9.78%
240 days
-9.78%
Maximum Daily Upside Volatility
60 days
+45.91%
Maximum Daily Downside Volatility
60 days
+47.83%
Liquidity
Average Turnover Rate
60 days
+0.05%
120 days
+0.06%
5 years
--
Turnover Deviation
20 days
-56.12%
60 days
-23.50%
120 days
-0.79%
Peer Comparison
Biotechnology & Medical Research
Evotec SE
EVO
6.06 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
